Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients
Identifieur interne : 000278 ( Pmc/Checkpoint ); précédent : 000277; suivant : 000279Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients
Auteurs : Khalid A. Alburikan [Arabie saoudite] ; Hatem A. Abuelizz [Arabie saoudite]Source :
- Saudi Pharmaceutical Journal : SPJ [ 1319-0164 ] ; 2019.
Abstract
Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a novel coronavirus that was identified in 2012 in Saudi Arabia. It is associated with significant mortality and morbidity. We identified factors associated with the Middle East Respiratory Syndrome-Coronavirus (MERS‐CoV) infection among suspected cases presented with sign and symptoms of upper respiratory infection or exposure to the virus. We also looked at the impact of medication history on virus transmission.
We included subjects with suspected MERS-CoV infection and confirmed cases of MERS infection. Subjects were excluded if there were any missing data that prevent the final analysis. Descriptive statistics were used to report demographic data. Percentages and frequencies were used to summarize the categorical variables, while means and standard deviations were calculated for continuous variables. Logistic regression was used to assess the risk of MERS-CoV infection among the suspected cases. A value of
A total of 16,189 suspected cases were identified, complete data were analyzed for 3154 to assess factors that are independently associated with MERS-CoV infection. MERS-CoV infection was associated with age (adjusted odds ratio [AOR] = 1.06; 95% CI [1.02–1.098], P-value = 0.004), male gender (AOR = 1.617; 95% CI [1.365–1.77], P-value < 0.001) and diabetes (AOR = 1.68; 95% CI [1.346–1.848], P-value = 0.002. There was no significant association with the other comorbidities. Medication history was not associated with an increase or decrease the likelihood of the infection.
MERS-Cov infection is more common in male, advanced age and diabetes. No medications were associated with an increase or decrease the likelihood of the infection. This is important to focus on screening and detection to this patient population.
Url:
DOI: 10.1016/j.jsps.2019.11.016
PubMed: 32042254
PubMed Central: 7000305
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:7000305Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients</title><author><name sortKey="Alburikan, Khalid A" sort="Alburikan, Khalid A" uniqKey="Alburikan K" first="Khalid A." last="Alburikan">Khalid A. Alburikan</name><affiliation wicri:level="1"><nlm:aff id="af005">Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia</nlm:aff><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author><author><name sortKey="Abuelizz, Hatem A" sort="Abuelizz, Hatem A" uniqKey="Abuelizz H" first="Hatem A." last="Abuelizz">Hatem A. Abuelizz</name><affiliation wicri:level="1"><nlm:aff id="af010">Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia</nlm:aff><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32042254</idno><idno type="pmc">7000305</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000305</idno><idno type="RBID">PMC:7000305</idno><idno type="doi">10.1016/j.jsps.2019.11.016</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">001139</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001139</idno><idno type="wicri:Area/Pmc/Curation">001139</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001139</idno><idno type="wicri:Area/Pmc/Checkpoint">000278</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000278</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients</title><author><name sortKey="Alburikan, Khalid A" sort="Alburikan, Khalid A" uniqKey="Alburikan K" first="Khalid A." last="Alburikan">Khalid A. Alburikan</name><affiliation wicri:level="1"><nlm:aff id="af005">Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia</nlm:aff><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author><author><name sortKey="Abuelizz, Hatem A" sort="Abuelizz, Hatem A" uniqKey="Abuelizz H" first="Hatem A." last="Abuelizz">Hatem A. Abuelizz</name><affiliation wicri:level="1"><nlm:aff id="af010">Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia</nlm:aff><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451</wicri:regionArea><wicri:noRegion>Riyadh 11451</wicri:noRegion></affiliation></author></analytic><series><title level="j">Saudi Pharmaceutical Journal : SPJ</title><idno type="ISSN">1319-0164</idno><idno type="eISSN">2213-7475</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a novel coronavirus that was identified in 2012 in Saudi Arabia. It is associated with significant mortality and morbidity. We identified factors associated with the Middle East Respiratory Syndrome-Coronavirus (MERS‐CoV) infection among suspected cases presented with sign and symptoms of upper respiratory infection or exposure to the virus. We also looked at the impact of medication history on virus transmission.</p></sec><sec><title>Method</title><p>We included subjects with suspected MERS-CoV infection and confirmed cases of MERS infection. Subjects were excluded if there were any missing data that prevent the final analysis. Descriptive statistics were used to report demographic data. Percentages and frequencies were used to summarize the categorical variables, while means and standard deviations were calculated for continuous variables. Logistic regression was used to assess the risk of MERS-CoV infection among the suspected cases. A value of <italic>p</italic> < 0.05 was considered statistically significant.</p></sec><sec><title>Results</title><p>A total of 16,189 suspected cases were identified, complete data were analyzed for 3154 to assess factors that are independently associated with MERS-CoV infection. MERS-CoV infection was associated with age (adjusted odds ratio [AOR] = 1.06; 95% CI [1.02–1.098], P-value = 0.004), male gender (AOR = 1.617; 95% CI [1.365–1.77], P-value < 0.001) and diabetes (AOR = 1.68; 95% CI [1.346–1.848], P-value = 0.002. There was no significant association with the other comorbidities. Medication history was not associated with an increase or decrease the likelihood of the infection.</p></sec><sec><title>Conclusions</title><p>MERS-Cov infection is more common in male, advanced age and diabetes. No medications were associated with an increase or decrease the likelihood of the infection. This is important to focus on screening and detection to this patient population.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Aleanizy, Fadilah Sfouq" uniqKey="Aleanizy F">Fadilah Sfouq Aleanizy</name></author><author><name sortKey="Mohmed, Nahla" uniqKey="Mohmed N">Nahla Mohmed</name></author><author><name sortKey="Alqahtani, Fulwah Y" uniqKey="Alqahtani F">Fulwah Y. Alqahtani</name></author><author><name sortKey="Mohamed, Rania Ali El Hadi" uniqKey="Mohamed R">Rania Ali El Hadi Mohamed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Assiri, Abdullah" uniqKey="Assiri A">Abdullah Assiri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, Jasper F W" uniqKey="Chan J">Jasper F.W. Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Xin" uniqKey="Chen X">Xin Chen</name></author><author><name sortKey="Chughtai, Abrar Ahmad" uniqKey="Chughtai A">Abrar Ahmad Chughtai</name></author><author><name sortKey="Dyda, Amalie" uniqKey="Dyda A">Amalie Dyda</name></author><author><name sortKey="Macintyre, Chandini Raina" uniqKey="Macintyre C">Chandini Raina MacIntyre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cotten, Matthew" uniqKey="Cotten M">Matthew Cotten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Groot, R J" uniqKey="De Groot R">R.J. de Groot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guery, Benoit" uniqKey="Guery B">Benoit Guery</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Raj, V Stalin" uniqKey="Raj V">V. Stalin Raj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rivers, Caitlin M" uniqKey="Rivers C">Caitlin M. Rivers</name></author><author><name sortKey="Majumder, Maimuna S" uniqKey="Majumder M">Maimuna S. Majumder</name></author><author><name sortKey="Lofgren, Eric T" uniqKey="Lofgren E">Eric T. Lofgren</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zumla, Alimuddin" uniqKey="Zumla A">Alimuddin Zumla</name></author><author><name sortKey="Hui, David S" uniqKey="Hui D">David S Hui</name></author><author><name sortKey="Perlman, Stanley" uniqKey="Perlman S">Stanley Perlman</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Saudi Pharm J</journal-id><journal-id journal-id-type="iso-abbrev">Saudi Pharm J</journal-id><journal-title-group><journal-title>Saudi Pharmaceutical Journal : SPJ</journal-title></journal-title-group><issn pub-type="ppub">1319-0164</issn><issn pub-type="epub">2213-7475</issn><publisher><publisher-name>Published by Elsevier B.V. on behalf of King Saud University.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32042254</article-id><article-id pub-id-type="pmc">7000305</article-id><article-id pub-id-type="publisher-id">S1319-0164(19)30166-5</article-id><article-id pub-id-type="doi">10.1016/j.jsps.2019.11.016</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Alburikan</surname><given-names>Khalid A.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Abuelizz</surname><given-names>Hatem A.</given-names></name><email>habuelizz@ksu.edu.sa</email><xref rid="af010" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="af005"><label>a</label>Department of Clincal Pharmacy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia</aff><aff id="af010"><label>b</label>Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia</aff><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author at: College of Pharmacy, King Saud University, P.O. Box 2475, Riyadh 11451, Saudi Arabia. <email>habuelizz@ksu.edu.sa</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>7</day><month>12</month><year>2019</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>2</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>7</day><month>12</month><year>2019</year></pub-date><volume>28</volume><issue>2</issue><fpage>161</fpage><lpage>164</lpage><history><date date-type="received"><day>11</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>© 2019 Published by Elsevier B.V. on behalf of King Saud University.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder></copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab005"><sec><title>Background</title><p>Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a novel coronavirus that was identified in 2012 in Saudi Arabia. It is associated with significant mortality and morbidity. We identified factors associated with the Middle East Respiratory Syndrome-Coronavirus (MERS‐CoV) infection among suspected cases presented with sign and symptoms of upper respiratory infection or exposure to the virus. We also looked at the impact of medication history on virus transmission.</p></sec><sec><title>Method</title><p>We included subjects with suspected MERS-CoV infection and confirmed cases of MERS infection. Subjects were excluded if there were any missing data that prevent the final analysis. Descriptive statistics were used to report demographic data. Percentages and frequencies were used to summarize the categorical variables, while means and standard deviations were calculated for continuous variables. Logistic regression was used to assess the risk of MERS-CoV infection among the suspected cases. A value of <italic>p</italic> < 0.05 was considered statistically significant.</p></sec><sec><title>Results</title><p>A total of 16,189 suspected cases were identified, complete data were analyzed for 3154 to assess factors that are independently associated with MERS-CoV infection. MERS-CoV infection was associated with age (adjusted odds ratio [AOR] = 1.06; 95% CI [1.02–1.098], P-value = 0.004), male gender (AOR = 1.617; 95% CI [1.365–1.77], P-value < 0.001) and diabetes (AOR = 1.68; 95% CI [1.346–1.848], P-value = 0.002. There was no significant association with the other comorbidities. Medication history was not associated with an increase or decrease the likelihood of the infection.</p></sec><sec><title>Conclusions</title><p>MERS-Cov infection is more common in male, advanced age and diabetes. No medications were associated with an increase or decrease the likelihood of the infection. This is important to focus on screening and detection to this patient population.</p></sec></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Middle East Respiratory Syndrome</kwd><kwd>MERS-CoV</kwd><kwd>Diabetes</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Alburikan, Khalid A" sort="Alburikan, Khalid A" uniqKey="Alburikan K" first="Khalid A." last="Alburikan">Khalid A. Alburikan</name></noRegion><name sortKey="Abuelizz, Hatem A" sort="Abuelizz, Hatem A" uniqKey="Abuelizz H" first="Hatem A." last="Abuelizz">Hatem A. Abuelizz</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000278 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000278 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:7000305
|texte= Identifying factors and target preventive therapies for Middle East Respiratory Syndrome sucsibtable patients
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:32042254" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |